A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

Blood. 2023 Nov 16;142(20):1752-1756. doi: 10.1182/blood.2023020858.

Abstract

Cellular ontogeny and MLL breakpoint site influence the capacity of MLL-edited CD34+ hematopoietic cells to initiate and recapitulate infant patients' features in pro-B-cell acute lymphoblastic leukemia (B-ALL). We provide key insights into the leukemogenic determinants of MLL-AF4+ infant B-ALL.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Gene Editing*
  • Hematopoietic Stem Cells
  • Humans
  • Infant
  • Myeloid-Lymphoid Leukemia Protein / genetics
  • Oncogene Proteins, Fusion / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / therapy

Substances

  • Myeloid-Lymphoid Leukemia Protein
  • Oncogene Proteins, Fusion